Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Keeping Pharma’s House in Order

Bribery and corruption are two major problems in any industry, and Big Pharma is not exempt. As regulators look to tackle this problem, coming down hard on perpetuators, pharma companies need to ensure that their compliance

Barry Vitou and Kim Green, Pinsent Masons (December 2012)

Keywords: Foreign Corrupt Practices Act (FCPA) UK Serious Fraud Office (SFO) Bribery Act 2010 Adequate Procedures Deferred Prosecution Agreements (DPAs)

    View full article    |    Back to Industry Insight section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |